The Christie Nhs Foundation Trust Uk
Manchester M20 4BX
3 studies enrolling now · 11 studies all time
What they study most
Adult-type Diffuse Gliomas, Advanced Solid Tumors, Advanced Solid Tumors Cancer, Bladder Cancer, CRC (Colorectal Cancer), Castration Resistant Prostate Cancer, Colorectal Cancer, ET (Essential Thrombocythemia), Follicular Lymphoma, Gastric/ Gastroesophageal Junction, Gastrointestinal (GI) Malignancies, Glioblastoma
Studies at this site
- A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer — Recruiting now
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
- A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. — Recruiting now
- Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Running, not enrolling
- Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations — Stopped early
- A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. — Running, not enrolling
- Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). — Completed
- Study of INCA 0186 in Subjects With Advanced Solid Tumors — Stopped early
- A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors — Completed
- A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors — Completed
- INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors — Completed